Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population

This is a preview of subscription content, log in to check access.

Figure 1

References

  1. 1.

    US-FDA 2016;Pageshttps://www.fda.gov/media/97468/download on 5/9/2019.

  2. 2.

    US-FDA 2016;Pages. Accessed at Drugs@FDA at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000SumR.pdf on 4/22/2019.

  3. 3.

    Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-107.

    Article  Google Scholar 

  4. 4.

    2013;Pageshttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf on 6/3/2019.

  5. 5.

    Kozlowski S, Birger N, Brereton S, McKean SJ, Wernecke M, Christl L, et al. Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population. JAMA. 2018;320(9):929-31.

    Article  Google Scholar 

Download references

Acknowledgments

We thank Dr. Sarah Dutcher of the Office of Surveillance and Epidemiology Center for Drug Evaluation and Research (CDER), US FDA, for analysis and interpretation of data and Dr. Sarah Yim of the Office of Therapeutic Biologics and Biosimilars in the Office of New Drugs, CDER, US FDA, for critical review of this manuscript. We also thank Mr. Victor Shiau of Acumen, LLC, for analysis and interpretation of data and Mr. Andrew Kwist of Acumen, LLC, for critical revision of this manuscript.

Funding

No external funding support; funding by FDA and CMS.

Author information

Affiliations

Authors

Contributions

Steven Kozlowski: initial conception and design of the work; analysis and interpretation of data; drafting and revision of the manuscript.

Natasha Flowers: analysis and interpretation of data; drafting and revision of manuscript.

Noy Birger: initial conception and design of the work; analysis and interpretation of data.

Michael Wernecke: initial conception and design of the work; analysis and interpretation of data; drafting and revision of manuscript.

Thomas E. MaCurdy: acquisition of data; obtained funding; study supervision.

Jeffrey A. Kelman: conception and design of the work; critical revision of manuscript for important content.

David J. Graham: conception and design of the work; analysis and interpretation of data; critical revision of manuscript for important content.

All authors agree with submission of draft manuscript.

Corresponding author

Correspondence to Steven Kozlowski MD.

Ethics declarations

This study was determined to meet the requirements of a Public Health Surveillance activity by the FDA/Center for Drug Evaluation and Research Human Subjects Protection Liaison to the FDA IRB.

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Disclaimer

This manuscript reflects the views of the authors and should not be construed to represent FDA’s or CMS’s views or policies.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kozlowski, S., Flowers, N., Birger, N. et al. Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population. J GEN INTERN MED (2020). https://doi.org/10.1007/s11606-020-05957-1

Download citation